BRD2 and ovarian carcinoma: The novelty of this work as new potential adjuvant therapy for ovarian cancer using gold nanoparticles is: (a) to protect miR-145 from ribonucleases and long noncoding RNAs (lncRNAs) that can act as sponges of miR-145, preventing its effects and (b) the incorporation of a FSH fragment in the architecture of the AuNP nanosystem to ensure that GNPF-miR-145 reaches only ovarian cancer cells [12].